IP Verse

Novartis Pharma Ag competitive analysis

Latest patents of Novartis Pharma Ag opposed by its competitors

Explore Novartis Pharma Ag's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 20, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP4218732
Mar 26, 2025Tablets Comprising Eltrombopag Olamine3
EP3143995
Jan 15, 2025A Rapamycin Derivative For Treating Lung Cancer7
EP3090730
Jul 3, 2024Novel Pharmaceutical Composition7
EP2784084
Oct 4, 2023Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof6
EP3345602
Apr 6, 2022Rapamycin Derivative For Treating Advanced Solid Tumours3
EP3003316
Jul 22, 2020Combination Therapies For Cancer1
EP2340828
Jul 15, 2020Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor8
EP3351246
Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis10
EP3342411
Aug 21, 2019Rapamycin Derivative For Treating Pancreas Cancer10
EP1983984
Mar 7, 2018Tuberous Sclerosis Treatment4

Latest PTAB cases involving Novartis Pharma Ag

Discover the latest PTAB cases involving Novartis Pharma Ag, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Novartis Pharma Ag with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 20, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
NOVARTIS6472 - 21
ETHYPHARM112 - -
GENERICS UK223 - - -
STADA ARZNEIMITTEL11331 - -